Sequenom Inc. Reaches New 12-Month Low at $2.45 (SQNM)
Sequenom (NASDAQ:SQNM) set a new 52-week low on Wednesday, American Banking & Market News reports. The company traded as low as $2.45 and last traded at $2.53, with a volume of 1,316,366 shares. The stock had previously closed at $2.50.
A number of research firms have recently commented on SQNM. Analysts at Wedbush reiterated an “outperform” rating on shares of Sequenom in a research note to investors on Thursday, July 25th. They now have a $5.00 price target on the stock. Separately, analysts at Maxim Group cut their price target on shares of Sequenom from $7.00 to $6.00 in a research note to investors on Thursday, July 25th. They now have a “buy” rating on the stock. Finally, analysts at Ladenburg Thalmann downgraded shares of Sequenom from a “buy” rating to a “neutral” rating in a research note to investors on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $6.75.
Sequenom has a 1-year low of $2.48 and a 1-year high of $5.36. The stock has a 50-day moving average of $2.84 and a 200-day moving average of $3.64. The company’s market cap is $289.6 million.
Sequenom (NASDAQ:SQNM) last posted its quarterly earnings results on Wednesday, July 24th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.22) by $0.05. The company had revenue of $24.50 million for the quarter, compared to the consensus estimate of $46.25 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The company’s quarterly revenue was up 91.0% on a year-over-year basis. Analysts expect that Sequenom will post $-0.91 EPS for the current fiscal year.
Manufactures DNA detection and sequencing equipment. The Company’s two business units combine to utilize their MassARRAY system, SNP assay portfolio, disease gene discovery programs and DNA sample repository.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.